Quest Diagnostics has introduced the first direct-to-consumer blood test to identify beta-amyloid protein levels, which are an indicator of Alzheimer’s disease risk. The $399 test can detect high amyloid levels years before signs of dementia develop. The test uses the same technology as a doctor-ordered blood test that Quest introduced earlier this year. Early detection of excessive amyloid levels can be beneficial because it allows people to undertake lifestyle modifications and join clinical trials, perhaps delaying or lowering their risk of Alzheimer’s. The test is intended for people over the age of 18 who have memory problems or a family history of Alzheimer’s disease and wish to know their risk. Users order the test online, and the order is reviewed by a telemedicine doctor. An independent panel reviews positive test results.

To know more: About the original article click here.